TCGA-D8-A3Z5-01A-41R-A24H-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 34
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.420
- MYOGENESIS+0.320
- ESTROGEN_RESPONSE_EARLY+0.280
- KRAS_SIGNALING_DN+0.220
- NOTCH_SIGNALING+0.220
- P53_PATHWAY+0.150
- APICAL_JUNCTION+0.060
- BILE_ACID_METABOLISM+0.040
- TNFA_SIGNALING_VIA_NFKB+0.030
- ESTROGEN_RESPONSE_LATE+0.010
Top 10 suppressed
- E2F_TARGETS-0.620
- MYC_TARGETS_V1-0.580
- G2M_CHECKPOINT-0.550
- PROTEIN_SECRETION-0.550
- MTORC1_SIGNALING-0.530
- INTERFERON_ALPHA_RESPONSE-0.430
- INTERFERON_GAMMA_RESPONSE-0.420
- ALLOGRAFT_REJECTION-0.410
- OXIDATIVE_PHOSPHORYLATION-0.400
- COMPLEMENT-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-W8-A86G-01A-21R-A36F-07 | — | A | 0.935 |
| 2 | SRR1313116 | — | A | 0.929 |
| 3 | TCGA-E2-A14U-01A-11R-A22K-07 | — | A | 0.927 |
| 4 | R76 | — | — | 0.910 |
| 5 | ERR2208935 | — | — | 0.892 |
| 6 | TCGA-A7-A426-01A-22R-A24H-07 | — | A | 0.884 |
| 7 | 9176b038-65e3-469d-a867-d99bc732e45d | — | — | 0.883 |
| 8 | SRR1313093 | — | B | 0.870 |
| 9 | TCGA-D8-A4Z1-01A-21R-A266-07 | — | A | 0.869 |
| 10 | TCGA-OL-A5RV-01A-12R-A28M-07 | — | A | 0.868 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.420 | Inavolisib | — uncovered |
| MYOGENESIS | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.220 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.010 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.010 | Inavolisib | — uncovered |